Boehringer Ingelheim invested €3.7 billion on R&D last year, the highest spend in its history, as it mobilised its scientists to seek out new therapies for COVID-19.
AstraZeneca has been rebuked by a US health authority after a trial monitoring board said data published from a large study of its COVID-19 vaccine may be out of date and may not give a rep
For the past year, life science companies around the world worked at breakneck speed to develop and manufacture safe and effective treatments to respond to the COVID-19 pandemic.